ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Above Fifty Day Moving Average – Here’s Why

Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $93.06 and traded as high as $97.00. ProShares Ultra Nasdaq Biotechnology shares last traded at $96.08, with a volume of 3,676 shares trading hands.

ProShares Ultra Nasdaq Biotechnology Price Performance

The business’s 50-day moving average is $93.78 and its 200 day moving average is $86.91. The firm has a market capitalization of $82.00 million, a P/E ratio of 20.68 and a beta of 1.20.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the third quarter valued at approximately $307,000. Franklin Resources Inc. bought a new position in ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth $32,000. Finally, Kaizen Financial Strategies raised its holdings in ProShares Ultra Nasdaq Biotechnology by 4.7% in the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock valued at $483,000 after acquiring an additional 250 shares in the last quarter.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.